Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease is under clinical development by Bayer and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease overview
Drug candidate is under development for the treatment of chronic obstructive pulmonary disease (COPD) with frequent exacerbation. It acts by targeting Prolyl Endopeptidase (PREP).
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease’s drug-specific PTSR and LoA scores, buy the report here.